Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 1/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25504933 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL29323260 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL25504875 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL25524899 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL10024720 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL15837375 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL16769132 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL17211042 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL25504930 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 | |
| SCHEMBL25504609 | 1.00 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624258-B2 | Polymorph of regadenoson | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2017-04-18 | — | — | US | disclosed |
| US-9580457-B2 | Process for the preparation of (1-{9-[(4S, 2R, 3R, 5R)-3, 4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl}pyrazole-4-yl)-N-methylcarboxamide | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2017-02-28 | — | — | US | disclosed |
| US-20160115191-A1 | Novel Polymorph of Regadenoson | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2016-04-28 | — | — | US | disclosed |
| US-20150353593-A1 | Novel Process for the Preparation of (1-pyrazole-4-yl)-N-methylcarboxamide | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115191-A1 | Novel Polymorph of Regadenoson | UGT1A6, PARP16, POLR1A | LGALS9 1426/4885LGALS1 798/4885LGALS3 678/4885 |
| US-20150353593-A1 | Novel Process for the Preparation of (1-pyrazole-4-yl)-N-methylcarboxamide | AADAC, PYCR1, CPS1 | LGALS9 3279/4885LGALS1 4040/4885LGALS3 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.